Ge
Non vérifié

Genentech

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté
16/11/2026
Industrie
Science
Biotechnologie
Industrie pharmaceutique
Santé Publique
Santé
Hygiène alimentaire
VIH, SIDA et maladies auto-immunes
Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy
1.00
10/11/2026
Événements
Industrie
Science
Biotechnologie
Médecine - Divers
Santé
Industrie pharmaceutique
Santé Publique
Genentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer’s Disease Portfolio at CTAD 2026
1.00
25/10/2026
Oncologie
Santé
Médecine - Divers
Santé Publique
Industrie pharmaceutique
Biotechnologie
Industrie
Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
1.00
23/10/2026
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Événements
Industrie
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
1.00
21/10/2026
Oncologie
Santé
Santé Publique
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
Expos
Industrie
Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026
1.00
19/10/2026
Oncologie
Santé
Biotechnologie
Médecine - Divers
Industrie pharmaceutique
Événements
Industrie
Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
1.00
16/10/2026
Science
Hygiène alimentaire
Médecine - Divers
Biotechnologie
Santé
Industrie pharmaceutique
Santé Publique
Optique
Industrie
FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
1.00
10/10/2026
Science
Biotechnologie
Industrie pharmaceutique
Optique
Santé
Hygiène alimentaire
Médecine - Divers
Industrie
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
1.00
09/10/2026
Industrie
Oncologie
Santé
Hygiène alimentaire
Médecine - Divers
Industrie pharmaceutique
Biotechnologie
FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0